This page is for general information. Consult a doctor for personal advice. Call emergency services if symptoms are severe.
How to use OMLYCLO 150 MG READY-TO-USE INJECTION SOLUTION IN PRE-FILLED SYRINGE
Introduction
Package Leaflet: Information for the User
Omlyclo 150 mg solution for injection in pre-filled syringe
omalizumab
This medicine is subject to additional monitoring, which will allow for quick identification of new safety information. You can help by reporting any side effects you may get. The last section of section 4 will tell you how to report side effects.
Read all of this leaflet carefully before you start using this medicine because it contains important information for you.
Keep this leaflet, you may need to read it again.
If you have any further questions, ask your doctor, pharmacist or nurse.
This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours.
If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. See section 4.
Contents of the pack
What is Omlyclo and what is it used for
What you need to know before you use Omlyclo
How to use Omlyclo
Possible side effects
Storage of Omlyclo
Contents of the pack and other information
1. What is Omlyclo and what is it used for
Omlyclo contains the active substance omalizumab. Omalizumab is a human protein, similar to the natural proteins produced by the body. It belongs to a class of medicines called monoclonal antibodies.
Omlyclo is used for the treatment of:
allergic asthma
chronic rhinosinusitis (inflammation of the nose and sinuses) with nasal polyps
chronic spontaneous urticaria (CSU)
Allergic asthma
This medicine is used to prevent asthma from getting worse by controlling symptoms of severe allergic asthma in adults, adolescents and children (from 6 years of age) who are already taking asthma medicines, but whose symptoms are not adequately controlled with medicines such as high-dose inhaled corticosteroids and inhaled beta-agonists.
Chronic rhinosinusitis with nasal polyps
This medicine is used to treat chronic rhinosinusitis with nasal polyps in adults (from 18 years of age) who are taking intranasal corticosteroids (nasal spray with corticosteroids), but whose symptoms are not well controlled with these medicines. Nasal polyps are small growths in the lining of the nose. Omlyclo helps to reduce the size of the polyps and improves symptoms including nasal congestion, loss of sense of smell, mucus in the back of the throat and nasal discharge.
Chronic spontaneous urticaria (CSU)
This medicine is used for the treatment of chronic spontaneous urticaria in adults and adolescents (from 12 years of age) who are already taking antihistamines but whose CSU symptoms are not well controlled by these medicines.
Omlyclo works by blocking a substance called immunoglobulin E (IgE) that is produced by the body. IgE is involved in a type of inflammation that plays a key role in causing allergic asthma, chronic rhinosinusitis with nasal polyps and CSU.
2. What you need to know before you use Omlyclo
Do not use Omlyclo
if you are allergic to omalizumab or any of the other ingredients of this medicine (listed in section 6).
If you think you may be allergic to any of the ingredients, tell your doctor, as you should not use Omlyclo.
Warnings and precautions
Tell your doctor before using Omlyclo:
if you have kidney or liver problems,
if you have a condition where your own immune system attacks parts of your own body (autoimmune disease),
if you are going to travel to an area where parasitic infections are common, as Omlyclo may reduce your resistance to such infections,
if you have had a severe allergic reaction (anaphylaxis) in the past, for example as a result of taking a medicine, an insect sting or food.
Omlyclo does not treat acute asthma symptoms, such as a sudden asthma attack. Therefore, Omlyclo should not be used to treat this type of symptom.
Omlyclo is not intended to prevent or treat other types of allergic conditions, such as sudden allergic reactions, hyperimmunoglobulin E syndrome (inherited immune disorder), aspergillosis (lung disease caused by a fungus), food allergy, eczema or hay fever, as Omlyclo has not been studied in these conditions.
Watch for signs of allergic reactions and other serious side effects
Omlyclo may cause serious side effects. You should watch for signs of these effects while using Omlyclo. Seek medical attention immediately if you notice any signs that indicate a serious allergic reaction or other serious side effects. These signs are mentioned in “Serious side effects” in section 4.
Before you or someone else injects Omlyclo, it is important that you receive training from your doctor on how to recognize the early symptoms of serious allergic reactions and how to act if they occur (see section 3, “How to use Omlyclo”). Most serious allergic reactions occur during the first three doses of Omlyclo.
Children and adolescents
Allergic asthma
Omlyclo is not recommended for children under 6 years of age. Its use in children under 6 years of age has not been studied.
Chronic rhinosinusitis with nasal polyps
Omlyclo is not recommended for children and adolescents under 18 years of age. Its use in patients under 18 years of age has not been studied.
Chronic spontaneous urticaria (CSU)
Omlyclo is not recommended for children under 12 years of age. Its use in children under 12 years of age has not been studied.
Other medicines and Omlyclo
Tell your doctor, pharmacist or nurse if you are taking, have recently taken or might take any other medicines.
This is especially important if you are using:
medicines to treat a parasitic infection, as Omlyclo may reduce the effect of your medicines,
inhaled corticosteroids and other medicines for allergic asthma.
Pregnancy and breastfeeding
If you are pregnant, think you may be pregnant or are planning to have a baby, ask your doctor for advice before taking this medicine. Your doctor will discuss with you the benefits and risks of using this medicine during pregnancy.
Tell your doctor immediately if you become pregnant while being treated with Omlyclo.
Omlyclo may pass into breast milk. If you are breastfeeding or plan to breastfeed, ask your doctor for advice before taking this medicine.
Driving and using machines
Omlyclo is unlikely to affect your ability to drive or use machines.
3. How to use Omlyclo
Follow exactly the instructions for administration of this medicine given by your doctor. If you are unsure, ask your doctor, pharmacist or nurse again.
How to use Omlyclo
Omlyclo is used as an injection under the skin (known as a subcutaneous injection).
Omlyclo injection
You and your doctor will decide if you will inject Omlyclo yourself. The first three doses will always be injected under the supervision of a healthcare professional (see section 2).
It is important that you have received proper training on how to inject the medicine before you do it yourself.
The caregiver (e.g. parents) can give the Omlyclo injection after proper training.
To get detailed instructions on how to inject Omlyclo, see “Instructions for use of Omlyclo in pre-filled syringe” at the end of this leaflet.
Training to recognize serious allergic reactions
It is also important that you do not inject Omlyclo yourself until your doctor or nurse has taught you:
how to recognize the signs and symptoms of serious allergic reactions,
what to do if the symptoms appear.
For more information on the signs and symptoms of serious allergic reactions, see section 4.
How much to use
Allergic asthma and chronic rhinosinusitis with nasal polyps
Your doctor will decide how much Omlyclo you need and how often you need to use it. This depends on your body weight and the results of a blood test done before starting treatment to determine the level of IgE in your blood.
You will need between 1 and 4 injections at the same time. You will need injections every 2 or 4 weeks.
Continue taking your current asthma and/or nasal polyp medicine while you are being treated with Omlyclo. Do not stop any asthma and/or nasal polyp medicine without talking to your doctor.
You may not notice an immediate improvement after starting treatment with Omlyclo. In patients with nasal polyps, the effects have been seen 4 weeks after starting treatment. In patients with asthma, it usually takes between 12 and 16 weeks for the medicine to have its full effect.
Chronic spontaneous urticaria (CSU)
You will need two 150 mg injections at the same time every 4 weeks.
Continue taking your current CSU medicine during treatment with Omlyclo. Do not stop any medicine without talking to your doctor.
Use in children and adolescents
Allergic asthma
Omlyclo can be used in children and adolescents from 6 years of age who are already taking asthma medicine, but whose asthma symptoms are not well controlled by medicines such as high-dose inhaled corticosteroids and inhaled beta-agonists. Your doctor will tell you how much Omlyclo your child needs and how often it should be given. This will depend on the child’s weight and the results of blood tests done before starting treatment to determine the level of IgE in the blood.
Children (from 6 to 11 years of age) are not expected to inject Omlyclo themselves. However, if the doctor thinks it is suitable, the caregiver can give the Omlyclo injection after proper training.
Chronic rhinosinusitis with nasal polyps
Omlyclo should not be used in children and adolescents under 18 years of age.
Chronic spontaneous urticaria (CSU)
Omlyclo can be used in adolescents from 12 years of age who are already taking antihistamines but whose CSU symptoms are not well controlled by these medicines. The dose for adolescents from 12 years of age is the same as for adults.
If you miss a dose of Omlyclo
If you have missed a visit, contact your doctor or hospital as soon as possible to reschedule.
If you have forgotten to inject a dose of Omlyclo, inject it as soon as you remember. Then talk to your doctor to find out when you should have your next dose.
If you stop treatment with Omlyclo
Do not stop treatment with Omlyclo unless your doctor tells you to. Stopping or finishing treatment with Omlyclo may cause your symptoms to come back.
However, if you are being treated for CSU, your doctor may stop treatment with Omlyclo from time to time to assess your symptoms. Follow your doctor’s instructions.
If you have any other questions about the use of this medicine, ask your doctor, pharmacist or nurse.
4. Possible side effects
Like all medicines, this medicine can cause side effects, although not everybody gets them. The side effects caused by Omlyclo are usually mild to moderate, but occasionally they can be serious.
Serious side effects:
Seek medical attention immediately if you notice any of the signs of the following side effects:
Rare (may affect up to 1 in 1,000 people)
serious allergic reactions (including anaphylaxis). Symptoms may include rash, itching, hives, swelling of the face, lips, tongue, larynx (voice box), trachea or other parts of the body, rapid heartbeat, dizziness and slight feeling of fainting, confusion, shortness of breath, wheezing or difficulty breathing, blue-tinged skin or lips, collapse and loss of consciousness. If you have a history of serious allergic reactions (anaphylaxis) not related to Omlyclo, you may be at greater risk of developing a serious allergic reaction after using Omlyclo.
systemic lupus erythematosus (SLE). Symptoms may include muscle pain, pain and swelling of the joints, rash, fever, weight loss and fatigue.
Frequency not known (cannot be estimated from the available data)
Churg-Strauss syndrome or hypereosinophilic syndrome. Symptoms may include one or more of the following: swelling, pain or rash around blood vessels or lymph nodes, high level of a specific type of white blood cell (marked eosinophilia), worsening of respiratory problems, nasal congestion, heart problems, pain, numbness, tingling in the arms and legs.
low blood platelet count with symptoms such as bleeding or bruising that occurs more easily than normal.
serum sickness. Symptoms may include one or more of the following: joint pain with or without swelling or stiffness, rash, fever, swelling of the lymph nodes, muscle pain.
Other side effects include:
Very common (may affect more than 1 in 10 people)
fever (in children)
Common (may affect up to 1 in 10 people)
injection site reactions including pain, swelling, itching and redness
pain in the upper abdomen
headache (very common in children)
infections of the upper respiratory tract, such as pharyngitis and common cold
feeling of pressure or pain in the cheeks and forehead (sinusitis, sinus headache)
joint pain (arthralgia)
feeling of dizziness
Uncommon (may affect up to 1 in 100 people)
feeling of sleepiness or tiredness
tingling or numbness of hands or feet
fainting, decrease in blood pressure when sitting or standing up (postural hypotension), flushing
sore throat, cough, acute respiratory problems
feeling of nausea, diarrhea, indigestion
itching, hives, rash, increased sensitivity of the skin to the sun
weight gain
flu-like symptoms
swollen arms
Rare (may affect up to 1 in 1,000 people)
parasitic infection
Frequency not known (cannot be estimated from the available data)
muscle pain and joint inflammation
hair loss
Reporting of side effects
If you experience any side effects, talk to your doctor, pharmacist or nurse, even if it is possible that they are not listed in this leaflet. You can also report side effects directly through the national reporting system listed in Appendix V. By reporting side effects, you can help provide more information on the safety of this medicine.
5. Storage of Omlyclo
Keep this medicine out of the sight and reach of children.
Do not use this medicine after the expiry date which is stated on the label after EXP. The expiry date is the last day of the month stated.
Store in the original package to protect from light.
Store in a refrigerator (2°C - 8°C). Do not freeze.
Do not use any packaging that is damaged or shows signs of deterioration.
6. Container Contents and Additional Information
Composition of Omlyclo
The active ingredient is omalizumab. A 1 ml syringe of solution contains 150 mg of omalizumab.
The other components are L-arginine hydrochloride, L-histidine monohydrate hydrochloride, L-histidine, polysorbate 20, and water for injectable preparations.
Appearance of Omlyclo and Container Contents
Omlyclo injectable solution is presented as a clear to turbid, colorless to light brownish-yellow solution in a pre-filled syringe.
Omlyclo 150 mg injectable solution is available in packs containing 1 pre-filled syringe and in multiple packs containing 6 (6 x 1) or 10 (10 x 1) pre-filled syringes.
Not all pack sizes may be marketed in your country.
Marketing Authorization Holder
Celltrion Healthcare Hungary Kft.
1062 Budapest
Váci út 1-3. WestEnd Office Building B tower
Hungary
Manufacturer
Nuvisan France SARL
2400, Route des Colles,
06410, Biot,
France
MIDAS Pharma GmbH
Rheinstrasse 49
55218 West Ingelheim Am Rhein
Rhineland-Palatinate
Germany
Kymos S.L.
Ronda de Can Fatjó 7B
Parc Tecnològic del Vallès
08290 Cerdanyola Del Valles
Barcelona
Spain
You can request more information about this medication by contacting the local representative of the marketing authorization holder:
Detailed information on this medicinal product is available on the European Medicines Agency website: http://www.ema.europa.eu
INSTRUCTIONS FOR USE OF OMLYCLO PRE-FILLED SYRINGE
Read and follow the instructions for use provided with Omlyclo pre-filled syringe before starting to use it and each time you get a replacement. They may contain new information.
This information does not replace consultation with your healthcare professional about your disease or treatment.
Children (from 6 to less than 12 years of age) should not self-inject Omlyclo pre-filled syringe; however, if the healthcare professional considers it appropriate, a caregiver may administer the injection after receiving proper training.
Omlyclo pre-filled syringe is available in 2 concentrations (see Figure A). These instructions should be followed for the 150 mg/1 ml concentration. The type of pre-filled syringe you receive will depend on the dose prescribed by your healthcare professional (see Figure C: Dosing Table). Check the label on the container and the color of the plunger rod to ensure that the concentration is correct.
Important Safety Information
Keep the pre-filled syringe out of sight and reach of children. The pre-filled syringe contains small parts.
Do notopen the sealed container until you are about to use the pre-filled syringe.
Do notuse the pre-filled syringe if the container seal or the plastic tray seal is broken, as it may not be safe to use.
Do notever leave the pre-filled syringe in a place where others may handle it.
Do notshake the pre-filled syringe.
Do notremove the cap until just before administering the injection.
The pre-filled syringe cannot be reused. Dispose of the used pre-filled syringe in a puncture-resistant container immediately after use (see step 13. Dispose of the pre-filled syringe).
Storage of the Pre-filled Syringe
Store the pre-filled syringe in the refrigerator between 2 °C and 8 °C. Keep this medicine closed in its container to protect it from light.
Do notfreeze the pre-filled syringe.
Remember to remove the pre-filled syringe from the refrigerator and let it reach room temperature (25 °C) for about 30 minutes before preparing it for injection. Keep the pre-filled syringe in the container to protect it from light.
The storage time of the pre-filled syringe at room temperature (25 °C) before use should not exceed 7 days.
Do notuse the pre-filled syringe after the expiration date shown on the container and on the pre-filled syringe label. If it has expired, return the entire container to the pharmacy.
Do notuse the pre-filled syringe if it has been dropped or is visibly damaged.
Parts of the Pre-filled Syringe (see Figure B)
Preparation for Injection
Gather materials for injection
1.a. Prepare a clean and flat surface, such as a table or counter, in a well-lit area.
1.b. Remove the container(s) containing the necessary pre-filled syringe(s) from the refrigerator to administer the prescribed dose.
Note: Depending on the dose prescribed by your healthcare professional, you may need to prepare one or more pre-filled syringes and inject the contents of all of them. The following table shows how many injections of each concentration are needed for the prescribed dose (see Figure C: Dosing Table).
1.c. Make sure you have the following materials:
Container containing the pre-filled syringe
Not included in the container:
1 alcohol swab
1 cotton ball or gauze
1 adhesive bandage
Puncture-resistant container
Check the expiration date on the container (see Figure D)
Do notuse it if the expiration date has passed. If the expiration date has passed, return the entire container to the pharmacy.
Wait 30 minutes
3.a. Leave the unopenedcontainer containing the pre-filled syringe at room temperature (25 °C) for 30 minutes to warm up (see Figure E).
Do notheat the pre-filled syringe using heat sources such as hot water or a microwave.
If the pre-filled syringe does not reach room temperature, the injection may be uncomfortable and make it difficult to push the plunger rod.
Wash your hands
4.a. Wash your hands with soap and water and dry them well (see Figure F).
Choose an injection site (see Figure G)
5.a. You can inject into:
The front of the thighs.
The lower abdomen, except for the 5 cm around the navel.
The outer aspect of the upper arm if you are a caregiver or healthcare professional.
Do notadminister the injection into moles, scars, bruises, or areas where the skin is sensitive, red, hard, or cracked.
Do notadminister the injection through clothing.
Choose a different injection site for each new injection, at least 2.5 cm away from the area used for the last injection.
Clean the injection site
6.a. Clean the injection site with an alcohol swab, making a circular motion (see Figure H).
6.b. Let the skin dry before injecting.
Do notblow or touch the injection site again before administering the injection.
Inspect the pre-filled syringe
7.a. Open the container.
Hold the body of the pre-filled syringe to lift it out of the tray.
7.b. Inspect the pre-filled syringe and ensure it has the correct medicine (Omlyclo) and dose.
7.c. Look at the pre-filled syringe and ensure it is not cracked or damaged.
7.d. Check the expiration date on the pre-filled syringe label (see Figure I).
Do notuse it if the expiration date has passed.
Note: If the expiration date is not visible in the viewing window, you can turn the inner cylinder of the pre-filled syringe until the expiration date is visible.
Inspect the medicine
8.a. Look at the medicine and confirm that the liquid is clear to turbid, colorless to light brownish-yellow, and has no particles (see Figure J).
Do notuse the pre-filled syringe if the liquid has changed color, is clearly turbid, or contains particles.
You may see air bubbles in the liquid. This is normal.
Administration of the Injection
Remove the cap
9.a. Hold the pre-filled syringe by the body with one hand. With the other hand, gently pull the cap to remove it.
Do nothold the plunger rod while removing the cap.
You may see a drop of liquid on the tip of the needle. This is normal.
9.b. Dispose of the cap immediately in a puncture-resistant container (see step 13. Dispose of the pre-filled syringeand Figure K).
Do notput the cap back on the pre-filled syringe.
Do notremove the cap until you are ready to administer the injection.
Do nottouch the needle. Otherwise, you could prick yourself with the needle.
Insert the pre-filled syringe into the injection site
10.a. Gently pinch a skin fold at the injection site with one hand.
Note: It is important to pinch the skin to ensure that you inject under the skin (in the fatty area) but not deeper (in the muscle).
10.b. With a quick and dart-like motion, insert the needle completely into the skin fold at an angle of 45 to 90 degrees (see Figure L).
Do nottouch the plunger rod while inserting the needle into the skin.
Administer the injection
11.a. Once the needle is inserted, release the skin fold.
11.b. Slowly push the plunger rod downuntil the entire dose of medicine is injected and the syringe is empty (see Figure M).
Do notchange the position of the pre-filled syringe once the injection has started.
If the plunger rod is not fully pressed, the needle guard will not extend to cover the needle when it is removed.
Remove the pre-filled syringe from the injection site
12.a. Once the pre-filled syringe is empty, slowly lift your thumb off the plunger rod until the needle is completely covered by the needle guard (see Figure N).
If the needle is not covered, proceed with caution to dispose of the syringe (see step 13. Dispose of the pre-filled syringe).
You may have some bleeding (see step 14. Injection site care).
In case of contact with the medicine, wash the area that has been in contact with the medicine with water.
Do notreuse the pre-filled syringe.
Do notrub the injection site.
After the Injection
Dispose of the pre-filled syringe
To dispose of the prefilled syringe.
13.a. Place the used prefilled syringe in
a puncture-resistant container
immediately after use (see Figure O).
Do notthrow (discard) the prefilled
syringe in household trash.
If you do not have a puncture-resistant
container, you may use a household
container that can be closed and is
resistant to punctures. For your safety
and health and that of others, used
needles and syringes should never be
reused. Disposal of unused medication
and all materials that have come into
contact with it will be carried out in
accordance with local regulations.
Medicines must notbe thrown
down the drain or into household
waste. Ask your pharmacist how to
dispose of the packaging and medicines
you no longer need. This will help
protect the environment.
Care of the injection site.
14.a. If bleeding occurs, treat the injection site by applying gentle pressure, without rubbing, with
a cotton swab or gauze at the site and apply an adhesive dressing if necessary.
This information is for reference only and does not constitute medical advice. Always consult a licensed doctor before taking any medication. Oladoctor is not responsible for medical decisions based on this content.
Alternatives to OMLYCLO 150 MG READY-TO-USE INJECTION SOLUTION IN PRE-FILLED SYRINGE
Online doctors for OMLYCLO 150 MG READY-TO-USE INJECTION SOLUTION IN PRE-FILLED SYRINGE
Discuss dosage, side effects, interactions, contraindications, and prescription renewal for OMLYCLO 150 MG READY-TO-USE INJECTION SOLUTION IN PRE-FILLED SYRINGE – subject to medical assessment and local rules.